Anavex Life Sciences Corp. Stock Forecast

NASDAQ:AVXL Open Broker Account

$11.89 (3.93%)

Volume: 777.956k

Closed: Nov 25, 2022

Hollow Logo Score: -4.012

Anavex Life Sciences Corp. Stock Forecast

$11.89 (3.93%)

Volume: 777.956k

Closed: Nov 25, 2022

Score Hollow Logo -4.012

AVXL Price Targets and Analyst Ratings NASDAQ:AVXL

Last Reaction
Be the first to comment on AVXL

AVXL Forecast. What You Should Know.

AVXL Historical Ratings and Targets

FAQ

What are analyst ratings?
Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts. Read More...

What to keep in mind using analyst ratings?
The best way to use analyst ratings is to supplement your investment research. Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Also, be sure to pay attention to the date of the rating. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Read More...

What is a price target in trading?
A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company's earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate. However, it can guide investors looking to buy or sell a stock. Read More...

Unlock All Premium Features! Go Premium! Only $9.95/Month

Unlock the Top 5 candidates in every list
Unlock full Ultimate List Builder
Golden Star lists & Auto Portfolios
Possible Runners & Moving Average lists
Ad-free browsing
Save data in PDF

Hot Stocks To Watch:

About Anavex Life Sciences Corp.

Anavex Life Sciences Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica... AVXL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT